- Home
- PLBY vs FATE Comparison
PLBY vs FATE Comparison
Compare PLBY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLBY | FATE |
|---|---|---|
| Founded | 1953 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 116.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PLBY | FATE |
|---|---|---|
| Price | $1.93 | $1.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.00 | ★ $3.92 |
| AVG Volume (30 Days) | 569.1K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,510,000.00 | $7,137,000.00 |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $8.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $0.66 |
| 52 Week High | $2.44 | $3.43 |
Technical Indicators
Market Signals| Indicator | PLBY | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 74.20 | 49.49 |
| Support Level | $1.57 | $1.04 |
| Resistance Level | $1.73 | $1.13 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 97.66 | 90.24 |
Price Performance
Historical ComparisonAbout PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.